title: Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France; Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France.
authors.forename: Mélanie
authors.initials: M
authors.lastname: Saint-Jean
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France; Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Quéreux
authors.affiliation: PIMESP, Saint-Jacques Hospital, Nantes, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Nguyen
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France; Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France.
authors.forename: Lucie
authors.initials: L
authors.lastname: Peuvrel
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France; Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France.
authors.forename: Anabelle
authors.initials: A
authors.lastname: Brocard
authors.affiliation: Department of Biochemistry, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Vallée
authors.affiliation: Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France; Immuno-Dermatology Laboratory, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Anne-Chantal
authors.initials: AC
authors.lastname: Knol
authors.affiliation: Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France; Immuno-Dermatology Laboratory, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Amir
authors.initials: A
authors.lastname: Khammari
authors.affiliation: Department of Biochemistry, University Hospital Hôtel-Dieu, Nantes, France.
authors.forename: Marc G
authors.initials: MG
authors.lastname: Denis
authors.affiliation: Department of Dermato-Cancerology, University Hospital Hôtel-Dieu, Nantes, France; Inserm U892, CIC Biothérapie Inserm 0503, Nantes, France; Immuno-Dermatology Laboratory, University Hospital Hôtel-Dieu, Nantes, France. Electronic address: brigitte.dreno@wanadoo.fr.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dréno
mesh_terms: D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
references.citation: N Engl J Med. 2010 Aug 26;363(9):809-19
references.pmid: 20818844
references.citation: N Engl J Med. 2011 Jun 30;364(26):2507-16
references.pmid: 21639808
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: PLoS One. 2012;7(1):e29336
references.pmid: 22235286
references.citation: Br J Cancer. 2011 Feb 1;104(3):464-8
references.pmid: 21224857
references.citation: Mol Cell Probes. 2004 Oct;18(5):349-52
references.pmid: 15294323
references.citation: Br J Dermatol. 2013 Apr;168(4):700-7
references.pmid: 23360189
references.citation: J Mol Diagn. 2013 Jan;15(1):70-80
references.pmid: 23159593
references.citation: Case Rep Oncol. 2012 May;5(2):280-9
references.pmid: 22740817
references.citation: J Clin Oncol. 2012 Jul 10;30(20):2522-9
references.pmid: 22614978